JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 96 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2018. The put-call ratio across all filers is 0.12 and the average weighting 1.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $549,000 | +17.1% | 234,294 | +51.4% | 0.01% | 0.0% |
| Q2 2022 | $469,000 | -51.0% | 154,728 | +9.7% | 0.01% | -44.4% |
| Q1 2022 | $958,000 | -25.6% | 141,090 | -8.5% | 0.01% | -25.0% |
| Q4 2021 | $1,288,000 | +48.6% | 154,190 | +32.0% | 0.01% | +33.3% |
| Q3 2021 | $867,000 | -2.0% | 116,784 | -10.2% | 0.01% | 0.0% |
| Q2 2021 | $885,000 | -58.7% | 130,012 | -37.7% | 0.01% | -65.4% |
| Q1 2021 | $2,144,000 | +330.5% | 208,812 | +837.2% | 0.03% | -29.7% |
| Q1 2018 | $498,000 | – | 22,280 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 4,447,829 | $30,245,000 | 89.29% |
| TRV GP III, LLC | 3,048,780 | $20,732,000 | 3.62% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 250,644 | $1,704,000 | 0.76% |
| PFM Health Sciences, LP | 3,262,833 | $22,187,000 | 0.70% |
| Yorktown Management & Research Co Inc | 56,600 | $385,000 | 0.30% |
| Sofinnova Investments, Inc. | 624,756 | $4,248,000 | 0.24% |
| Omega Fund Management, LLC | 275,513 | $1,873,000 | 0.21% |
| PATHWAY CAPITAL MANAGEMENT, LP | 60,279 | $410,000 | 0.16% |
| Orbimed Advisors | 2,147,400 | $14,602,000 | 0.15% |
| Grace Capital | 18,669 | $127,000 | 0.08% |